Dr. Verma Discusses Biosimilars in the Oncology Sphere

Sunil Verma, MD
Published: Monday, Mar 26, 2018



Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses biosimilars in the oncology sphere.

There are at least 7 new biosimilars that are currently being investigated, says Verma. In Europe, there was a recent approval of a biosimilar from Samsung Bioepis based on a neoadjuvant study. The FDA recently approved a trastuzumab (Herceptin) biosimilar from Mylan, MYL-1401O (Ogivri; trastuzumab-dkst), based on the HERiTAge study.

The approval of the trastuzumab biosimilar was based on data for early-stage breast cancer, but was also extrapolated to the gastric cancer setting. Issues with the implication of biosimilars into practice include interchangeability, automatic substitution, and extrapolation, says Verma. Clinicians need to familiarize themselves with these factors, as well as the implications of the biosimilar framework for regulatory agencies, when incorporating biosimilars into practice, he explains.


Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses biosimilars in the oncology sphere.

There are at least 7 new biosimilars that are currently being investigated, says Verma. In Europe, there was a recent approval of a biosimilar from Samsung Bioepis based on a neoadjuvant study. The FDA recently approved a trastuzumab (Herceptin) biosimilar from Mylan, MYL-1401O (Ogivri; trastuzumab-dkst), based on the HERiTAge study.

The approval of the trastuzumab biosimilar was based on data for early-stage breast cancer, but was also extrapolated to the gastric cancer setting. Issues with the implication of biosimilars into practice include interchangeability, automatic substitution, and extrapolation, says Verma. Clinicians need to familiarize themselves with these factors, as well as the implications of the biosimilar framework for regulatory agencies, when incorporating biosimilars into practice, he explains.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Bridging the Gaps Around Oncology Biosimilars: Assessing the Potential Impact of Emerging Agents to PracticeSep 29, 20181.5
Advent of Oncology Monoclonal Antibody Biosimilars ‒ A European Perspective OnlineNov 30, 20183.0
Publication Bottom Border
Border Publication
x